We target Auto-Immune Diseases
Ermium Therapeutics is developing orally available drug candidates allowing the efficient control of type 1 interferons.
These drug candidates have the potential to address a wide range of chronic auto-immune diseases, affecting millions of people worldwide and include type I interferon-mediated diseases.
In response to an unknown trigger, the immune system may attack the body’s own tissues weakening . Treatment for autoimmune diseases generally focuses on reducing immune system activity.
Severity Of Auto-Immune Diseases
There are more than 80 autoimmune diseases. While some are well known and include for instance Rheumatoid arthritis, Systemic lupus erythematosus, Inflammatory bowel diseases, Multiple sclerosis and type 1 diabetes mellitus, other are rare and difficult to diagnose.
The world prevalence of auto-immune diseases is increasing and they affect up to 10% of the population in Europe and North America.
Most of these diseases have no cure and the most serious conditions require lifelong treatment to ease symptoms.
- general immunosuppressants such as steroids, colchicine, methotrexate,
- biologics that have to be injected are targeting specific component of the immune system (TNFalpha, IL-1beta, IL-6, CD20, B cell growth factor, etc.)
- JAK inhibitors which are small molecules which help immune cells to lower the release inflammatory signals.